

From Pharma to AGI Hype, and Developing AI in Finance: Martin Shkreli’s Journey
Gradient Dissent
Episode Description
In this episode of Gradient Dissent, Lukas Biewald talks with Martin Shkreli — the infamous "pharma bro" turned founder — about his path from hedge fund manager and pharma CEO to convicted felon and now software entrepreneur. Shkreli shares his side of the drug pricing controversy, reflects on his prison experience, and explains how he rebuilt his life and business after being "canceled." They dive deep into AI and drug discovery, where Shkreli delivers a strong critique of mainstream approaches. He also talks about his latest venture in finance software, building Godel Terminal “a Vim for traders", and why he thinks the AI hype cycle is just beginning. It's a wide-ranging and candid conversation with one of the most controversial figures in tech and biotech. Follow Martin Shkreli on Twitter Godel Terminal: https://godelterminal.com/ Follow Weights & Biases on Twitter https://www.linkedin.com/company/wandb Join the Weights & Biases Discord Server: https://discord.gg/CkZKRNnaf3
Processing in Progress
This episode is being processed. The AI summary will be available soon. Currently transcribing audio...
Related Episodes

Why Physical AI Needed a Completely New Data Stack
Gradient Dissent
1h 0m

The Engineering Behind the World’s Most Advanced Video AI
Gradient Dissent
14m
The CEO Behind the Fastest-Growing AI Inference Company | Tuhin Srivastava
Gradient Dissent
59m
The Startup Powering The Data Behind AGI
Gradient Dissent
56m

Arvind Jain on Building Glean and the Future of Enterprise AI
Gradient Dissent
43m

How DeepL Built a Translation Powerhouse with AI with CEO Jarek Kutylowski
Gradient Dissent
42m
No comments yet
Be the first to comment